Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,596.00+3.70%ETH$2,433.02+6.42%GOLD$4,072.20+3.34%OIL$88.04-8.38%
Smart Investors Daily
SID Premium
KT

NASDAQ · KTTA

Pasithea Therapeutics Corp.

Healthcare · Biotechnology

$0.53

Up+$0.00 (+0.00%)

Updated Nov 4, 2026, 10:33 PM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
8.37M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.28 – $2.06
Volume
21.78M
Avg. volume
6.91M

Price performance · KTTA

KTTA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

KTTA closed at $0.53 after 21 trading sessions, up 18.57% for the selected period.

Last close
$0.53
Period change
+18.57%
Period low
$0.37
Period high
$0.53
Daily close
View OHLC price history
KTTA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.365$0.5344$0.3454$0.5321.78M
Nov 2, 2026$0.3847$0.3989$0.3501$0.368247.65K
Oct 30, 2026$0.359$0.3885$0.359$0.3702100.16K
Oct 29, 2026$0.3812$0.4074$0.35$0.3696329.82K
Oct 28, 2026$0.3908$0.40$0.3686$0.393596.82K
Oct 27, 2026$0.395$0.425$0.3713$0.3973649.43K
Oct 26, 2026$0.3956$0.412$0.372$0.3999628.87K
Oct 23, 2026$0.45$0.471$0.3448$0.40491.53M
Oct 22, 2026$0.488$0.50$0.445$0.4452379.12K
Oct 21, 2026$0.4249$0.4974$0.4198$0.4878782.03K
Oct 20, 2026$0.413$0.4151$0.41$0.4138.5K
Oct 19, 2026$0.4431$0.4431$0.41$0.412318.54K
Oct 16, 2026$0.4101$0.43$0.40$0.42209.31K
Oct 15, 2026$0.4094$0.4385$0.398$0.410120.57K
Oct 14, 2026$0.4399$0.4399$0.383$0.4094617.88K
Oct 13, 2026$0.45$0.45$0.41$0.423861.88K
Oct 12, 2026$0.4661$0.4661$0.4474$0.447580.71K
Oct 9, 2026$0.45$0.4675$0.45$0.467560.59K
Oct 8, 2026$0.4522$0.4675$0.4409$0.440956.16K
Oct 7, 2026$0.4473$0.4676$0.4401$0.4434132.49K
Oct 6, 2026$0.465$0.465$0.4401$0.44764.43K

Latest KTTA news

The latest Smart Investors Daily articles mentioning KTTA.

Stock researchCompany · Overview

KTTA research

Overview

Company profile and research snapshot.

Company profile

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$3.00
Implied upside
—
Analysts
7
KTTA recent ratings
DateFirmRatingTarget
Jun 16, 2026HC Wainwright & Co.Buy—
Apr 20, 2026HC Wainwright & Co.Buy—
Dec 8, 2025HC Wainwright & Co.Buy—
Jul 10, 2023EF HuttonBuy—
Apr 3, 2023EF HuttonBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026

Rebecca M. Brown, MD, and Kavita Sarin, MD, PhD, will join management to discuss unmet needs and the treatment landscape for NF1-associated cutaneous and plexiform neurofibromasMIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including neurofibromatosis type 1 (NF1) associated

Yahoo · Oct 23, 2026

Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026

-- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once daily PAS-004 for over 500 days despite recurrent, metastatic melanoma carrying the BRAF V600E mutation and prior progression on targeted combination therapy with dabrafenib and trametinib. -- Long-Term Tolerability: Overall, the safety profile of PAS-004 in the heavily pre-treated advanced cancer popu

Yahoo · Sep 14, 2026

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation - The European Neurofibromatosis Conference 2026 will take place in Vienna, Austria, from November 12–14, 2026 MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By